Lars Petter Jordheim

Summary

Country: France

Publications

  1. ncbi request reprint Therapeutic perspectives for cN-II in cancer
    Lars Petter Jordheim
    Centre de Recherche en Cancérologie de Lyon, INSERM U1052 CNRS UMR 5286, Faculté Rockefeller, 8 avenue Rockefeller, 69008 Lyon, France
    Curr Med Chem 20:4292-303. 2013
  2. doi request reprint Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
    Lars Petter Jordheim
    University of Lyon, F 69000 Lyon, France
    Biomark Med 7:663-71. 2013
  3. doi request reprint Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
    Lars Petter Jordheim
    Anticancer Antibody Team, Institut National de la Santé et de la Recherche Médicale U1052, Centre national de la recherche scientifique UMR 5286, Cancer Research Center of Lyon, Faculté Rockefeller, 8 Ave Rockefeller, 69008 Lyon, France
    Nat Rev Drug Discov 12:447-64. 2013
  4. doi request reprint Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells
    Lars Petter Jordheim
    Universite de Lyon, INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
    Mol Pharmacol 84:12-24. 2013
  5. doi request reprint Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening
    Lars Petter Jordheim
    Universite de Lyon, F 69000 Lyon, France
    Biochem Pharmacol 85:497-506. 2013
  6. pmc Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2
    Tú Nguyen-Dumont
    Genetic Cancer Susceptibility Group, IARC, 69372 Lyon, France
    BMC Med Genomics 4:39. 2011
  7. doi request reprint The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer
    Lars Petter Jordheim
    INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, Universite Claude Bernard Lyon I, 69008 Lyon, France
    Lancet Oncol 12:693-702. 2011
  8. ncbi request reprint Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells
    Lars Petter Jordheim
    INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, 8, avenue Rockefeller, 69008, Lyon, France
    Cancer Chemother Pharmacol 58:547-54. 2006
  9. ncbi request reprint [Cytotoxic nucleoside analogues--metabolism, activity and resistance]
    Lars Petter Jordheim
    INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, 8 avenue Rockefeller, 69008 Lyon, France
    Tidsskr Nor Laegeforen 125:2348-50. 2005
  10. doi request reprint Bacterial deoxyribonucleoside kinases are poor suicide genes in mammalian cells
    Claire Hebrard
    INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, Universite Claude Bernard Lyon I, Lyon, France
    Nucleosides Nucleotides Nucleic Acids 28:1068-75. 2009

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Therapeutic perspectives for cN-II in cancer
    Lars Petter Jordheim
    Centre de Recherche en Cancérologie de Lyon, INSERM U1052 CNRS UMR 5286, Faculté Rockefeller, 8 avenue Rockefeller, 69008 Lyon, France
    Curr Med Chem 20:4292-303. 2013
    ..Preliminary in vitro data and cancer cell models using cN-II inhibitors have already suggested the pivotal role of this enzyme as therapeutic target allowing the improvement of anticancer treatments. ..
  2. doi request reprint Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
    Lars Petter Jordheim
    University of Lyon, F 69000 Lyon, France
    Biomark Med 7:663-71. 2013
    ..The data that is currently available would benefit from the completion of well-designed randomized trials in order to confirm the clinical value of hENT1 and RRM1 as biomarkers in pancreatic cancer patients. ..
  3. doi request reprint Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
    Lars Petter Jordheim
    Anticancer Antibody Team, Institut National de la Santé et de la Recherche Médicale U1052, Centre national de la recherche scientifique UMR 5286, Cancer Research Center of Lyon, Faculté Rockefeller, 8 Ave Rockefeller, 69008 Lyon, France
    Nat Rev Drug Discov 12:447-64. 2013
    ..We also highlight the different approaches used in the development of these drugs and the potential of personalized therapy...
  4. doi request reprint Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells
    Lars Petter Jordheim
    Universite de Lyon, INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France
    Mol Pharmacol 84:12-24. 2013
    ..This study shows that small molecules targeting the protein-protein interaction of ERCC1 and XPF can be developed to enhance the effects of alkylating agents on cancer cells...
  5. doi request reprint Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening
    Lars Petter Jordheim
    Universite de Lyon, F 69000 Lyon, France
    Biochem Pharmacol 85:497-506. 2013
    ..This study showed that virtual screening is a useful tool for the identification of potent cN-II inhibitors, and our biological results indicated interesting activity for one lead compound that can be further developed as therapeutics...
  6. pmc Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2
    Tú Nguyen-Dumont
    Genetic Cancer Susceptibility Group, IARC, 69372 Lyon, France
    BMC Med Genomics 4:39. 2011
    ..We aimed to assess whether CHEK2 was subject to DAE in lymphoblastoid cell lines (LCLs) from high-risk breast cancer patients for whom no mutation in BRCA1 or BRCA2 had been identified...
  7. doi request reprint The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer
    Lars Petter Jordheim
    INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, Universite Claude Bernard Lyon I, 69008 Lyon, France
    Lancet Oncol 12:693-702. 2011
    ..Here, we review preclinical and clinical studies of RRM1 assessment and discuss the further steps in the development of this clinically pertinent biomarker...
  8. ncbi request reprint Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells
    Lars Petter Jordheim
    INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, 8, avenue Rockefeller, 69008, Lyon, France
    Cancer Chemother Pharmacol 58:547-54. 2006
    ..Some strategies to overcome this mechanism of resistance have been proposed there by gene transfer based therapy...
  9. ncbi request reprint [Cytotoxic nucleoside analogues--metabolism, activity and resistance]
    Lars Petter Jordheim
    INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, 8 avenue Rockefeller, 69008 Lyon, France
    Tidsskr Nor Laegeforen 125:2348-50. 2005
    ..Studies on cellular models and clinical samples have allowed insight into the mechanisms behind this resistance...
  10. doi request reprint Bacterial deoxyribonucleoside kinases are poor suicide genes in mammalian cells
    Claire Hebrard
    INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, Universite Claude Bernard Lyon I, Lyon, France
    Nucleosides Nucleotides Nucleic Acids 28:1068-75. 2009
    ..The fusion of dAK from Bacillus cereus to the green fluorescent protein induced a modest sensitization. Apparently, bacterial dNKs did not get properly expressed or are unstable in the mammalian cell...
  11. ncbi request reprint Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells
    Lars Petter Jordheim
    Laboratoire de Cytologie Analytique, 8, avenue Rockefeller, 69008 Lyon, France
    Mol Cancer Ther 4:1268-76. 2005
    ....
  12. doi request reprint Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors
    Ines Tagoug
    Universite de Lyon, Lyon, France
    Clin Cancer Res 19:3556-66. 2013
    ..Bortezomib, the first-in-class proteasome inhibitor, has displayed significant antitumor activity in multiple myeloma...
  13. doi request reprint Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin
    Lars Petter Jordheim
    Universite de Lyon, F 69008 Lyon, France
    Int J Antimicrob Agents 39:444-7. 2012
    ..Nucleoside analogues have antimicrobial activity and these results could be used for further identification and development of new antibiotics...
  14. ncbi request reprint Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug
    Lars Petter Jordheim
    INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, Universite Claude Bernard Lyon I, Lyon, France
    Clin Cancer Res 10:5614-21. 2004
    ..These results suggest that reduced deoxycytidine kinase expression is a mechanism of resistance to gemcitabine that is relevant in vivo and can be circumvented by a prodrug approach...